Management and clinical challenges of lupus nephritis presenting with hypotension: a case report
DOI:
https://doi.org/10.18203/2394-6040.ijcmph20250332Keywords:
Lupus nephritis, Systemic lupus erythematosus, Rheumatoid arthritis, Hypotension, Acute kidney injury, Immunosuppressive therapyAbstract
Lupus nephritis (LN), a grave sequel of systemic lupus erythematosus (SLE), precipitates substantial renal impairment and engenders noteworthy clinical morbidity. This case report delineates the presentation of a 39-year-old female with antecedent diagnoses of SLE and rheumatoid arthritis, who presented with severe dyspnea (Grade 4), retrosternal chest pain radiating posteriorly, and oliguria. Physical examination unveiled profound hypotension, while initial diagnostic evaluations were congruent with acute kidney injury indicative of LN. Despite robust fluid resuscitation, the patient hypotension persisted, necessitating intricate clinical deliberations. This case encapsulates the multifaceted challenges inherent in the management of lupus nephritis, particularly when complicated by refractory hypotension and multi-organ involvement. It accentuates the imperativeness of prompt diagnostic acuity and an integrative therapeutic paradigm. Additionally, it elucidates the rationale underpinning pivotal clinical decisions while addressing the nuances of such a formidable clinical scenario.
Metrics
References
Doria A, Iaccarino L, Ghirardello A, Zampieri S, Arienti S, Sarzi-Puttini P, et al. Clinical Rel. Am J Med. 2006;8(119):700-6. DOI: https://doi.org/10.1016/j.amjmed.2005.11.034
Slight-Webb S, Guthridge JM, Chakravarty EF, Chen H, Lu R, Macwana S, et al. Mycophenolate mofetil reduces STAT3 phosphorylation in systemic lupus erythematosus patients. JCI Insight. 2019;4(2):124202. DOI: https://doi.org/10.1172/jci.insight.124575
Wang ZR, Ren LM, Li R, Guan X, Han QM, Liu ML, et al. Analysis of 20-year survival rate and prognostic indicators of systemic lupus erythematosus. Zhonghua Yi Xue Za Zhi. 2019;99(3):178-82.
Rojas-Rivera JE, García-Carro C, Ávila AI, Espino M, Espinosa M, Fernández-Juárez G, et al. Diagnosis and treatment of lupus nephritis: a summary of the consensus document of the spanish group for the study of glomerular diseases (GLOSEN). Clini Kid J. 2023;16(9):1384-402. DOI: https://doi.org/10.1093/ckj/sfad055
Wilson HR, Medjeral-Thomas NR, Gilmore AC, Trivedi P, Seyb K, Farzaneh-Far R, et al. Glomerular membrane attack complex is not a reliable marker of ongoing C5 activation in lupus nephritis. Kidney Int. 2019;95(3):655-65. DOI: https://doi.org/10.1016/j.kint.2018.09.027
Uribe AG, Vilá LM, McGwin G, Sanchez ML, Reveille JD, Alarcón GS. The systemic lupus activity measure-revised, the Mexican systemic lupus erythematosus disease activity index (SLEDAI), and a modified SLEDAI-2K are adequate instruments to measure disease activity in systemic lupus erythematosus. J Rheumatol. 2004;31(10):1934-40.
Ingelfinger JR. Hematuria in adults. New England journal of medicine. 2021;385(2):153-63. DOI: https://doi.org/10.1056/NEJMra1604481
Zhang C, Qiu J, Huang Y, Tan R. Prophylactic norepinephrine infusion to treat hypotension after spinal anaesthesia during caesarean section: a meta-analysis. J Obst Gynaecol. 2024;44(1):2393379. DOI: https://doi.org/10.1080/01443615.2024.2393379
Chen X, Ye P, Wei D, Li QC, Li T. Hydrocortisone-induced blood pressure reduction in a patient with anterior pituitary hypofunction: a case report. Europ J Hosp Pharm. 2023;30(6):31. DOI: https://doi.org/10.1136/ejhpharm-2022-003590
Pazderska A, Pearce SH. Adrenal insufficiency–recognition and management. Clinical Med. 2017;17(3):258-62. DOI: https://doi.org/10.7861/clinmedicine.17-3-258
Adeva-Andany MM, Fernández-Fernández C, Mouriño-Bayolo D, Castro-Quintela E, Domínguez-Montero A. Sodium bicarbonate therapy in patients with metabolic acidosis. Sci World J. 2014;2(1):627673. DOI: https://doi.org/10.1155/2014/627673
Abbasifard M, Khorramdelazad H, Rostamian A, Rezaian M, Askari PS, Sharifi GT, et al. Effects of N-acetylcysteine on systemic lupus erythematosus disease activity and its associated complications: a randomized double-blind clinical trial study. Trials. 2023;24(1):129. DOI: https://doi.org/10.1186/s13063-023-07083-9
Dima A, Jurcut C, Chasset F, Felten R, Arnaud L. Hydroxychloroquine in systemic lupus erythematosus: overview of current knowledge. Therapeutic Adv Musculosk Dis. 2022;14:175-91. DOI: https://doi.org/10.1177/1759720X211073001
Takayama A, Fukasawa T, Takeuchi M, Kawakami K. Comparative renoprotective effectiveness of allopurinol and febuxostat among hyperuricemic patients with preserved kidney function. Modern Rheumatol. 2024;2:115. DOI: https://doi.org/10.1093/mr/roae115